At Vision Share, we are committed to highlighting innovations that support global sight restoration. Today, we’re putting the spotlight on Moria Surgical’s XTRA4, a next-generation hypothermic storage medium designed to extend corneal preservation. With FDA 510(k) clearance recently granted, XTRA4 allows preservation for up to 14 days.
Why Storage Innovation Matters
Currently, hypothermic storage solutions have a limited practical window for corneal transplantation. In the U.S., many surgeons avoid using tissue stored for longer than seven days, often resulting in unused corneas despite adequate viability. This constraint reduces flexibility, creates logistical challenges, and limits access for patients in need.
What Makes XTRA4 Different
Jana Tothova, Group Head of R&D at Moria, says, “This storage medium is the result of many years of research, testing, and development. By fine-tuning its ingredients, we were able to recreate the physiological conditions of the cornea during storage.”
XTRA4 replaces dextran with a different deswelling agent, helping maintain the cornea’s natural state. The result is a storage medium that prevents swelling, preserves transparency, and protects endothelial cells from stress. Tissue quality remains stable for up to 14 days at 2–8°C — doubling the practical window for surgical use.
Benefits for Surgeons and Eye Banks
- For surgeons: Consistent tissue thickness, improved transparency, and stable DSAEK grafts promise smoother procedures and stronger outcomes.
- For eye banks: No workflow changes. XTRA4 is packaged like existing media, with a 24-month shelf life, making adoption seamless.
Looking Ahead
Preliminary evidence suggests XTRA4 may preserve tissue beyond 14 days, opening the door for future FDA extensions. If adopted broadly, this innovation could reduce wasted tissue, expand surgical opportunities, and improve global access to vision-restoring procedures.
As Elisa Valguarnera, Product Manager at Moria, noted, collaboration with eye banks worldwide was key to bringing XTRA4 to market. “We want to thank VisionGift, Eversight, the Eye Bank of Venice, Italy, and other eye banks for partnering with us. They all played an important role in helping us bring this product to market, further strengthening Moria’s role as a partner in the Cornea Journey.”
That spirit of partnership goes hand in hand with Vision Share’s desire to connect surgeons, researchers, and eye banks so that every donated tissue has the greatest possible impact. XTRA4 marks an important step forward in corneal preservation, easing time constraints and expanding possibilities for sight restoration worldwide.
About Moria and XTRA4
Founded in France in 1820, Moria is one of the most recognized companies for its know-how in the manufacture of instruments for ophthalmic microsurgery, equipment for refractive surgery, and transplant surgery.
Moria has commissioned a white paper summarizing the results of the evaluation studies. To request a copy, please contact Moria@moria-int.com. XTRA4 will be available to order in the USA from mid-October 2025. For further information on availability, please contact Doug Cubic at doug@moriausa.com.
About Vision Share
Vision Share is a 501(c)(3) nonprofit organization and proudly represents the world’s largest network of eye banks. Each member eye bank is Eye Bank Association of America (EBAA) certified and registered with the Food and Drug Administration (FDA). Guided by a shared vision, Vision Share pools resources to provide surgeons with dependable, high-quality ocular tissue tailored to their specific needs. The Vision Share network has delivered over 141,000 corneas worldwide, transforming lives and restoring sight.
